LOGIN OR REGISTER
Course Library

NLA- SAP Module 3- Contemporary Management of Dyslipidemia: Lipid Guidelines V2

Cardiology
Credits:
19.75 AMA PRA Category 1 Credit(s) ™ 19.7 ANCC Contact Hours 19.75 ACPE 19 CDR
Launch Date:
November 16, 2016
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Lipidologists, Lipid Specialists, Cardiologists, Endocrinologists, Internists, Nephrologists, Primary Care Physicians, Family Practitioners, PhDs, Physicians Assistants, Cardiovascular Nurses, Nurse Practitioners, Pharmacists, Dietitians

Relevant Terms:

Guidelines

See Faculty section below for a complete list of faculty.

See Faculty section below for a complete list of faculty.

1. Analyze the effectiveness of risk assessment approaches from different organizations for the management of dyslipidemia.
2. Recognize differences in lipid management recommendations for special populations.
3. Compare and contrast established guidelines and recommendations for the management of dyslipidemia.
4. Review representative clinical cases in the management of patients with dyslipidemia.
5. Review recommendations for managing dyslipidemia relative to a specific disease state utilizing guidelines from other organizations.
6. Describe the principles of lipid management for cardiovascular disease prevention in patients with chronic kidney disease, type 2 diabetes, metabolic syndrome, and HIV.
7. Review the appropriate management of dyslipidemia in specific patient populations, including women, children, elderly and ethnic minorities.

CRITERIA FOR SUCCESS<>
In order to receive credit for this enduring program, participants must answer each question, review the ensuing critiques and evaluate the activity. A statement of credit will be available upon completion of an evaluation form. If you have questions about this CME/ CE activity, please contact the NLA at cme@lipid.org.<>
 <>
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.<>
 <>
Physicians who complete a program evaluation will receive a Statement of Continuing Education Credit from the NLA for up to 19.75 hours of AMA PRA Category 1 Credits™ toward the AMA Physician Recognition Award. To receive credit you must obtain a 30% or greater total score on your Performance Score Report.<>
 <>
COMMERCIAL SUPPORT<>
There is no commercial support for this activity.<>
 <>
CREDIT DESIGNATION<>
CME credit provided by the National Lipid Association
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this enduring activity for a maximum of 19.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 19 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.<>
 <> CE Credit provided by Postgraduate Institute for Medicine
 <>
Pharmacists<>
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number 0809-9999-16-456-H01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 19.75 contact hour(s) (1.975 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 19.7 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
 <>
This self-assessment program is recognized for Maintenance of Certification by the American Board of Clinical Lipidology and Renewal of Certification by the Accreditation Council for Clinical Lipidology.<>
 <>
FACULTY<>
Editor-in-Chief<>
Carl E. Orringer, MD, FNLA*<>
Associate Professor of Medicine<>
University of Miami Miller School of Medicine<>
Miami, FL<> <>
 <>
Associate Editor<>
Pamela B. Morris, MD, FNLA*<>
Director, Seinsheimer Cardiovascular Health Program<>
Co-Director, Women's Heart Care<>
Medical University of South Carolina<>
Charleston, SC  <>
 <>
Contributing Editors<>
Kim K. Birtcher, MS, PharmD, FNLA†<>
Clinical Professor<>
University of Houston College of Pharmacy<>
Houston, TX<>
 <>
Kellie H. McLain, ANP-BC†<>
Cardiology/Lipid Program<>
Medical University of South Carolina<>
Mt. Pleasant, SC<> <>
 <>
*Denotes Diplomate, American Board of Clinical Lipidology.<>
†Denotes Diplomate, Accreditation Council for Clinical Lipidology.<> <>
 <>
DISCLOSURES<>
Kim K. Birtcher, MS, PharmD, FNLA has received honorarium from Jones & Bartlett. Dr. Birtcher’s spouse is employed by Walgreens.<>
 <>
Kellie H. McLain, ANP-BC has nothing to disclose.<>
 <>
Pamela B. Morris, MD, FNLA has served on the advisory board for Amgen, AstraZeneca, LP, and Sanofi US and Regeneron Pharmaceuticals.<>
 <>
Carl E. Orringer, MD, FNLA has nothing to disclose.<>
 <>
Reviewer:<>
Nicole Woodsmall, MSH, RDN has nothing to disclose.<>
 <>
CME Reviewer:<>
Mahmoud A. Hamdan, MD, CDE has nothing to disclose.<> <>
 <>
NLA staff has nothing to disclose.<>
PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.<>
 <> <>
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.<>
 <>
DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME. <>
 <>
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.<> <> <> <> <>
 <>
COURSE VIEWING REQUIREMENTS<>
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 		 Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.



 

Schedule an event with a Standardized Patient
×